Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
- Combination Cancer Immunotherapy Market By 15 Different Cancers
- Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report:
https://www.kuickresearch.com/report-combination-cancer-therapy-market
The four main treatment methods used in the management of lymphoma are chemotherapy, radiation therapy, targeted therapy and immunotherapy. While all of these have successfully demonstrated positive results in millions of patients over the years, it cannot be denied that patients often develop resistance to these calling for another modality of treatment which can overcome this barrier. Combination therapies emerged as the solution for this, along with providing additional benefits such as increasing the efficacy and decreasing the duration of treatment. Combination therapies are some of the most prescribed treatments for a variety of cancer types because of the high response rate of patients towards the treatment.
Compared to leukemia, there are more clinical trials evaluating the efficacy of combinations of drugs and therapies to treat lymphoma. The number of drugs in clinical pipeline can be accredited to the growing popularity of combination therapies in the treatment and management of different forms of cancer. With an increase in the number of patients suffering from lymphoma, research activities have seen a surge in the last couple of years. Several key market players such as Bristol-Myers Squibb, Janssen, Genentech and AstraZeneca have been investing in the development of combinational therapies against lymphoma because of the lack of highly efficient treatments.
Over 50 trials have been registered in the clinical trials database and a majority of them are in early stages of clinical trials. TTX-030, a first-in-class CD39 targeting antibody developed by Trishula Therapeutics in collaboration with AbbVie, is being studied in a phase I clinical trial in combination with Keytruda, Gemzar and nab paclitaxel for the treatment of lymphoma. A combination of NIR178 and PDR001 is being tested in another trial which is being conducted by Novartis for diffuse large B-cell lymphoma. The study is in phase II of clinical trial and is estimated to end in November, 2022.
After the approval of the first CAR-T therapy, Kymriah, for lymphoma, the development of cell therapies against lymphoma has seen a jump. Kymriah has shown tremendous success in the market and Novartis has earned millions through its Kymriah sales. Following in the footprints of Novartis, many companies have developed CAR-T and other cell based therapies which are in now clinical trials. For instance, Shenzhen Geno-Immune Medical Institute, that already has multiple cell therapies in clinical trials for both solid and blood cancers, also has a CAR-T therapy under development for lymphoma. The infusion comprises of a concoction of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and other CAR-Ts as boosters intended for the treatment of patients with highly resistant B cell lymphomas. The therapy has entered phase II of clinical trials and is anticipated to get completed by mid-2023. AbbVie and Calibr (a division of Scripps Research) have collaborated for the development of combination therapy using CLBR001, a CAR-T therapy developed by Calibr and SWI019, developed by AbbVie. The combination is a first-in-class switchable CAR-T therapy targeting the B cell antigen CD19.
Apart from these, a gene therapy developed by MultiVir is also in phase II of trials for lymphoma and solid cancers. Ad-p53 is an adenoviral p53 gene therapy administered with approved immune checkpoint inhibitors to increase the efficacy of the treatment. The p53 is inactivated in cancer and Ad-p53 is designed to carry the p53 gene to limit cancer growth in the patient.
Compared to other forms of cancer, management of lymphoma has seen the introduction of many new types of treatments which have not been looked into for other indications. The diversity in these modes of action provides patients and doctors the flexibility to choose from multiple options as is seen beneficial for the patients. Many new targets are been looked into for the treatment of lymphoma including the BTK protein. BTK inhibitors have shown favorable activity in several B-cell malignancies and in the future, we may see BTK inhibitors and other novel drugs and therapies enter the clinical pipeline and the market.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com